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CLN1 disease, also called infantile neuronal ceroid lipofuscinosis (NCL) or infantile Batten disease, is a fatal neurodegenerative
lysosomal storage disorder resulting from mutations in the CLN1 gene encoding the soluble lysosomal enzyme palmitoylprotein thioesterase 1 (PPT1). Therapies for CLN1 disease have proven challenging because of the aggressive disease course
and the need to treat widespread areas of the brain and spinal cord. Indeed, gene therapy has proven less effective for CLN1
disease than for other similar lysosomal enzyme deficiencies. We therefore tested the efficacy of enzyme replacement
therapy (ERT) by administering monthly infusions of recombinant human PPT1 (rhPPT1) to PPT1-deficient mice (Cln1–/–) and
CLN1R151X sheep to assess how to potentially scale up for translation. In Cln1–/– mice, intracerebrovascular (i.c.v.) rhPPT1 delivery
was the most effective route of administration, resulting in therapeutically relevant CNS levels of PPT1 activity. rhPPT1treated mice had improved motor function, reduced disease-associated pathology, and diminished neuronal loss. In CLN1R151X
sheep, i.c.v. infusions resulted in widespread rhPPT1 distribution and positive treatment effects measured by quantitative
structural MRI and neuropathology. This study demonstrates the feasibility and therapeutic efficacy of i.c.v. rhPPT1 ERT.
These findings represent a key step toward clinical testing of ERT in children with CLN1 disease and highlight the importance
of a cross-species approach to developing a successful treatment strategy.

Introduction

In contrast to other monogenic causes of neurodegeneration such
as mitochondrial and peroxisomal disease (1, 2), the majority of
fatal lysosomal storage disorders (LSDs) are caused by a deficiency in proteins that are amenable to exogenous supply (3). These
are soluble lysosomal enzymes that can be secreted and taken up
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by cells via mannose-6-phosphate receptors (MPRs) in a process
named “cross-correction” (4). Nonetheless, the blood-brain barrier prevents systemically delivered enzyme replacement therapy (ERT) from reaching the CNS, unless its uptake properties are
modified (5). Intracerebrovascular (i.c.v.) delivery of recombinant
enzyme is therefore an attractive option to overcome this problem
and deliver ERT directly to the brain. However, across more than
40 neuronopathic LSDs, only 1 has an approved treatment available (6), so CNS-directed ERT still lacks general principles and
procedures. Obstacles to developing ERT include manufacturing appropriately glycosylated and phosphorylated recombinant
enzymes, defining appropriate dosing regimens, and delivering
enzymes to reach all affected CNS regions (3). Importantly, there
is a particular unmet need to scale up preclinical advances made in
mouse models to large animal models to maximize the chances of
successful clinical translation.
CLN1 disease, also called infantile neuronal ceroid lipofuscinosis (NCL) or infantile Batten disease, is a rapidly progressing,
devastating neurodegenerative LSD (7). The classic form of CLN1
disease begins in infancy and can present as early as 6 months of
1
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age. However, some mutations in this gene result in more delayed
presentations according to the precise mutation (8, 9). Its clinical
manifestations include sensory and motor deficits, visual impairment leading to blindness, and epileptic seizures (10). Because
there is currently no effective therapy, all cases are fatal (11, 12),
with a life expectancy of 9 to 12 years (10). This disease results
from mutations in the CLN1 gene that encodes the soluble lysosomal enzyme palmitoyl protein thioesterase 1 (PPT1) (9, 13).
Although CLN1 disease is theoretically amenable to an ERT strategy, developing this approach represents a greater challenge than
for other LSDs. This is due to its early onset and aggressive disease course and the need to treat widespread regions of the CNS
including both the brain and spinal cord (14, 15).
We have previously shown that administration of a single
intrathecal (i.t.) or intravenous (i.v.) dose of recombinant human
PPT1 (rhPPT1) to neonatal PPT1-deficient mice (Cln1−/−) produced modest effects on behavior and pathology (16–18). Because
exogenously supplied rhPPT1 has a finite half-life (16), we hypothesized that repeated dosing of the CNS would be required to provide a translatable therapy.
In this study, we tested this repeated dosing strategy first in
Cln1−/− mice, a well-established and -characterized model recapitulating most aspects of classical CLN1 disease (14, 15, 19), using a
previously defined dose and frequency based on the enzyme’s halflife (16). We then applied the same strategy to a recently generated
sheep model of CLN1 disease (20) that carries the most common
human disease–causing null mutation (CLN1R151X). In this strategy,
we used infusion parameters similar to those used in other large animal models of LSDs (21, 22). This sheep model allowed the assessment of enzyme biodistribution and dosing in a species with a brain
size and complexity that approximates that of the human brain.
We determined the therapeutic efficacy of i.c.v. delivery of
rhPPT1 into the cerebrospinal fluid (CSF) in Cln1−/− mice. In addition to the well-characterized brain pathology in CLN1 disease,
we recently highlighted the involvement of the spinal cord early in
disease progression (15, 23). Therefore, we also compared the efficacy of i.t. delivery into the lumbosacral space and a dual delivery
approach combining i.c.v. and i.t. infusions of the same total dose
of enzyme to determine the best route of administration in Cln1−/−
mice, before moving to test rhPPT1 in sheep.
Our data show that repeated dosing of rhPPT1 is an effective
therapy in animal models of CLN1 disease across different species. These results represent a key step toward clinical testing of
ERT in children with CLN1 disease.

Results

In vitro characterization and i.c.v. delivery of rhPPT1. The rhPPT1
used in this study was expressed and purified as previously
described (17). Western blotting showed a molecular weight just
below 37 kDa (Figure 1A), consistent with the previously reported
migration of rhPPT1 as a 34 kDa band in an SDS-PAGE gel (17)
(see full gel in Supplemental Figure 7). To ensure that this rhPPT1
preparation had properties appropriate for in vivo use, we determined additional biochemical characterizations of the enzyme.
The half-maximal binding (KD) of rhPPT1 to the MPR was 2.8 nM
(Figure 1B). Approximately 64% of the total rhPPT1 loaded onto
a cation-independent mannose-6-phosphate receptor (CI-MPR)
2

affinity column was retained on the column (Figure 1C). Analysis
of site-specific glycosylation revealed that the asparagine residues
Asn170, Asn185, and Asn205 were highly glycosylated. Asn170
contained 29% biphosphorylation and 15% monophosphorylation, Asn185 was 71% monophosphorylated, and Asn205 contained 23% biphosphorylation and 36% monophosphorylation.
These biochemical properties were favorable for the binding and
uptake of our rhPPT1 and its use in an ERT strategy.
We next tested the capability of monthly i.c.v. infusions of 20
μg rhPPT1 (5 μL of a 4 mg/mL solution) to increase the level of
enzymatically active PPT1 in the CNS of Cln1−/− mice. This dose
and infusion frequency in mice were chosen on the basis of our
previous dose-response studies following a single i.t. infusion of
rhPPT1 into Cln1−/− mice (16) and the relative persistence of PPT1
enzyme activity within the CNS (16).
In the current study, we collected brain and spinal cord tissue
from mice 24 hours after the final infusion at 6 months. Delivery
of rhPPT1 i.c.v. resulted in a statistically significant increase in
PPT1 activity within the CNS of Cln1−/− mice when compared with
vehicle-treated control mice, which had virtually undetectable
levels of PPT1 activity (Figure 1D). This elevation in PPT1 activity
was seen in both the brain (~64% of WT) and spinal cord (~38% of
WT) of rhPPT1-treated mice. We previously showed that a reduction in the secondary elevation of other lysosomal enzymes that
accompanies PPT1 deficiency can serve as a biochemical surrogate of therapeutic response in Cln1−/− mice (23, 24). Six-monthold vehicle-treated Cln1−/− mice had elevated levels of β-glucuronidase activity compared with WT controls. We found that
β-glucuronidase activity was statistically significantly reduced in
Cln1−/− mice receiving i.c.v. rhPPT1 infusions compared with their
vehicle-treated counterparts (Figure 1E).
Intracerebroventricular administration of rhPPT1 significantly
improves motor performance in Cln1−/− mice. We first determined
whether monthly i.c.v. infusions of the same 20 μg dose of rhPPT1
would ameliorate previously characterized behavioral phenotypes
in Cln1−/− mice. Semiautomated gait analysis revealed that Cln1−/−
mice treated i.c.v. with vehicle displayed an early period of hypermobility followed by a general decline in overall mobility starting
at 4 months, with statistically significant effects on overall speed,
cadence, and limb movement (Figure 2A). This performance
was comparable to our previous gait analysis data from untreated Cln1−/− mice (15, 23). In contrast, the group treated i.c.v. with
rhPPT1 had improved gait performance. We noted statistically
significant differences between the i.c.v. rhPPT1–treated and i.c.v.
vehicle–treated groups across most gait parameters, with a gait
performance of i.c.v. rhPPT1–treated Cln1−/− mice that was more
similar to that of WT controls (Figure 2A).
We previously demonstrated decreased rotarod performance of Cln1−/− mice as compared with WT controls beginning
at 5 months of age (25, 26). Therefore, we also tested WT, i.c.v.
rhPPT1–treated, and i.c.v. vehicle–treated Cln1−/− mice on both
stationary and constant speed rotarod paradigms. In the constant
speed rotarod test, both i.c.v. rhPPT1– and vehicle–treated groups
showed impaired performance at 5 and 6 months compared with
their WT counterparts (Figure 2B), but this was not statistically
significant. In contrast, in the stationary paradigm, while i.c.v.
vehicle–treated mice had a statistically significantly shorter laten-
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Figure 1. rhPPT1 enzyme characterization and in vivo efficacy in Cln1–/– mice. (A) Representative Western blot image of staining for PPT1 protein (~37
kDa) from CHO cell lysates (see full gel in Supplemental Figure 7). (B and C) rhPPT1 assay for binding to immobilized CI-MPR showing the (B) half-maximal
binding (KD) of rhPPT1 at 2.78 nM and maximum binding (Bmax) at 38.32 nM and (C) that 64% of the loaded rhPPT1 remained bound to the affinity
column. Specific activity in nmol/mg/h of (D) PPT1 and (E) β-glucuronidase enzymes from homogenates collected from mice 24 hours after their last i.c.v.
infusion showing statistically significantly increased PPT1 activity and reduced β-glucuronidase activity in both the brains and spinal cords of treated mice
(PPT1 i.c.v.) as compared with vehicle-treated controls (Veh i.c.v.). However, these enzyme values were not normalized to levels in WT control mice. Data
represent the mean ± SEM; n = 10. *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001, by 1-way ANOVA with post hoc Bonferroni’s correction (see
Supplemental Data File 2 for full P values).

cy to fall at 6 months (Figure 2B), i.c.v. rhPPT1–treated mice performed as well as their WT counterparts.
Intracerebroventricular administration of rhPPT1 significantly
attenuates Cln1−/− neuropathology. The brains and spinal cords of
i.c.v. rhPPT1– and vehicle–treated mice were analyzed for neuropathological markers in well-established regions of known
pathology. These included the primary somatosensory barrel field
(S1BF), the ventral posterior nuclei of the thalamus (VPM/VPL),
and the ventral horn of the cervical and lumbosacral spinal cord
(14, 15). Vehicle-treated Cln1−/− mice had statistically significantly
elevated levels of activated astrocytes (Figure 3A) and microglia
(Figure 3B) across all CNS regions. These levels were statistically
significantly reduced in i.c.v. rhPPT1–treated Cln1−/− mice (Figure

3, A and B). Similarly, the statistically significantly increased levels of intralysosomal subunit C of mitochondrial ATP synthase
(SCMAS) present in all CNS regions in the vehicle-treated group
were statistically significantly reduced in the i.c.v. rhPPT1–treated
group (Figure 4A). Statistically significant neuron loss and cortical
atrophy are observed in the brains and spinal cords of Cln1−/− mice
at end stage (14, 15, 23, 27) and were also seen in i.c.v. vehicle–
treated Cln1−/− mice, with statistically significantly fewer neurons
in the brain and spinal cord. In contrast, i.c.v. rhPPT1–treated mice
showed statistically significantly reduced neuron loss across all
regions (Figure 4B). These i.c.v. rhPPT1–treated mice also showed
statistically significantly less cortical atrophy (Figure 4C) compared with the i.c.v. vehicle–treated controls.

J Clin Invest. 2022;132(20):e163107 https://doi.org/10.1172/JCI163107
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Figure 2. Improved motor performance in i.c.v. treated Cln1–/– mice. (A) Semiautomated gait analysis measures of average speed (cm/s), cadence (steps/
second), maximum variation of speed (percentage), stride length (cm), standing time (s), swing time (s), swing speed (cm/s), and step cycle (s) from
1–6 months, showing an overall improved performance of mice treated i.c.v. with PPT1 (PPT1 i.c.v.) compared with mice treated i.c.v. with vehicle (Veh
i.c.v.), and similar to WT values. (B) Stationary and constant speed rotarod tests in 5- and 6-month-old mice. The mice treated i.c.v. with PPT1 performed
similarly to WT mice, whereas mice treated i.c.v. with vehicle had a statistically significant reduction in latency to fall (s) in the stationary rotarod test at
6 months. Both PPT1- and vehicle-treated mice showed a reduced latency to fall at 6 months in the constant speed rotarod test, but this did not reach
statistical significance. Data represent the mean ± SEM; n = 10. *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001; ##P < 0.01 (WT vs. i.c.v vehicletreated mice), by 2-way, mixed-effects ANOVA with post hoc Bonferroni’s correction (see Supplemental Data File 2 for full P values).

Alternate delivery routes are not as effective as i.c.v. delivery alone.
The spinal cord is severely affected in Cln1−/− mice, starting in the
early stages of disease progression (15, 16, 23). Therefore, we also
tested whether delivering monthly i.t. injections of the same 20 μg
dose of rhPPT1 to Cln1−/− mice would improve the treatment outcomes compared with i.c.v. infusions alone. We also tested a dual
delivery strategy by infusing the same total 20 μg dose of rhPPT1
via both the i.c.v. and i.t. routes, with half the dose (10 μg or 2.5 μL
4 mg/mL rhPPT1) delivered via each route.
For both i.t. rhPPT1–treated mice as well a combination of
i.c.v. and i.t. rhPPT1 deliveries, we observed a statistically significant increase in PPT1 enzyme activity in the brains and spinal cords of Cln1−/− mice (Supplemental Figure 1A; supplemental
material available online with this article; https://doi.org/10.1172/
JCI163107DS1) and a decrease in β-glucuronidase activity (Supplemental Figure 1B) as compared with vehicle-treated controls.
Mice treated i.t. with rhPPT1 outperformed i.t. vehicle–treated
Cln1−/− mice at 6 months on the stationary rotarod and at 5 and
4

6 months on the constant-speed rotarod (Supplemental Figure
2B). However, dual delivery of rhPPT1 via both i.c.v. and i.t. routes
did not show statistically significant treatment effects in either
rotarod test (Supplemental Figure 2B and Supplemental Figure
3B). Furthermore, compared with i.c.v. rhPPT1–treated mice, both
i.t. delivery alone and dual delivery of rhPPT1 had less effect on
the gait performance of Cln1−/− mice (Supplemental Figure 2A and
Supplemental Figure 3A).
Using neuropathological outcome measures, i.t. administration of rhPPT1 and dual delivery rhPPT1-treated Cln1−/−
mice displayed a variety of treatment effects, some of which
were statistically significantly different from those seen in the
vehicle-treated control mice. These effects varied across CNS
regions and varied for astrocytosis (Supplemental Figure 4A),
microglial activation (Supplemental Figure 4B), storage material accumulation (Supplemental Figure 5A), neuron survival, and
cortical thickness (Supplemental Figure 5B). However, neither
of these alternative delivery routes had a level of rescue across
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Figure 3. Decreased astrocytosis and microglial activation in the brains and spinal cords of i.c.v. treated Cln1–/– mice. Representative immunofluorescence images and thresholding image analysis showing an overall statistically significant reduction in (A) astrocytosis (GFAP) and (B) microglial activation
(CD68) in i.c.v. treated (PPT1 i.c.v.) compared with vehicle-treated (Veh i.c.v.) mice across the S1BF, VPM/VPL, and cervical and lumbar spinal cord (SC).
However, these did not reach WT levels across any of the regions except for CD68 in the S1BF. Scale bars: 100 μm. Data represent the mean ± SEM; n = 6.
**P < 0.01, ***P < 0.001, and ****P < 0.0001, by 1-way ANOVA with post hoc Bonferroni’s correction (see Supplemental Data File 2 for full P values).

all pathological phenotypes comparable to that provided by i.c.v.
administration of rhPPT1 alone.
Intracerebroventricular administration of rhPPT1 in CLN1R151X
sheep. We next sought to scale up the repeated i.c.v. rhPPT1 dosing
strategy in a larger and more complex CNS. We first confirmed
that a single dose of rhPPT1 would elevate PPT1 activity in the
CNS of the recently generated CLN1R151X sheep model (20). Four
6-month-old homozygous CLN1R151X sheep were infused with a
single dose of rhPPT1. The scaled up dose of 4 mg rhPPT1 (1 mL
total volume of the same 4 mg/mL enzyme preparation used in
the Cln1−/− mice) was based on practical considerations of the volume and rate of infusion, while minimizing the anesthetic risk,
and was delivered using infusion parameters similar to those
used when delivering ERT to tripeptidyl peptidase 1–deficient
(TPP1-deficient) dogs (21, 22).

Sheep that received a single 4 mg dose of i.c.v. rhPPT1 were
sacrificed 24 hours, 1 week, 2 weeks, or 1 month after the infusion. PPT1 activity in the CSF was found to be increased to 92% of
WT activity 24 hours after administration. Thereafter, it dropped
to 7%, 3%, and 3% at 1 week, 2 weeks, and 1 month after dosing,
respectively. At 24 hours, PPT1 activity was elevated across multiple brain regions including the subventricular zone (12.6% of
WT), cortex (1.1% of WT), midbrain (0.9% of WT), and brainstem
(2.9% of WT). This level of PPT1 activity progressively decreased
in animals sacrificed 1 week, 2 weeks, or 1 month after infusion
(Supplemental Figure 6).
To test the therapeutic efficacy of i.c.v. rhPPT1, 6-month-old (early symptomatic) homozygous CLN1R151X sheep (20) (n = 2) received
over 7 months a monthly i.c.v. infusion of 4 mg rhPPT1 from the same
batch of enzyme as that used in Cln1−/− mice (1 mL of 4 mg/mL for
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Figure 4. Decreased storage material accumulation, improved neuron survival, and cortical atrophy in i.c.v. treated Cln1–/– mice. (A) Representative
immunofluorescence images and thresholding image analysis of SCMAS levels showing an overall statistically significant reduction in i.c.v. treated mouse
brains and spinal cords compared with vehicle-treated mice across the S1BF, VPM/VPL, and SC. However, these did not reach WT levels across any of
the regions. Scale bar: 100 μm. Statistically significant improvements in (B) neuron counts across all regions and (C) reduced cortical atrophy (S1BF) in
PPT1-treated mice compared with vehicle-treated mice, but not completely normalized to WT values. Data represent the mean ± SEM; n = 6. **P < 0.01,
***P < 0.001, and ****P < 0.0001, by 1-Way ANOVA with post hoc Bonferroni’s correction (see Supplemental Data File 2 for full P values).

each infusion), with the same infusion ports and parameters previously used when delivering rhTPP1 to CLN2-deficient dogs (21, 22).
The rhPPT1-treated CLN1R151X sheep were sacrificed at 13 months of
age, along with 2 age-matched WT and 2 untreated CLN1R151X sheep.
The CSF levels in the rhPPT1-treated sheep showed increases of up
to 150% of WT PPT1 enzyme activity levels 1 week after the final
administration of rhPPT1 (Supplemental Figure 6).
All sheep underwent structural MRI of the brain within 1 hour
of sacrifice, following removal of the metal ports used for transfusions. Cortical gray matter (GM) regions undergo differential
degrees of atrophy in CLN1R151X homozygous animals (20). Gross
anatomical examination of brains collected at autopsy revealed
pronounced cerebral and cerebellar atrophy in the untreated
CLN1R151X sheep compared with WT sheep brains. In contrast,
rhPPT1-treated CLN1R151X sheep brains showed less atrophy of both
the forebrain and cerebellum (Figure 5A). MRI analysis showed a
6

similar protective effect of rhPPT1 administration in rhPPT1-treated CLN1R151X sheep (Figure 5B). To assess the relative preservation
of cortical regions, even in the presence of underlying GM atrophy,
we normalized regional GM volumes to total GM volume (summarized in Supplemental Data File 1 and Supplemental Table 1). After
atlas-based segmentation, histograms of the thickness of individual cortical regions were compared across experimental groups in
each of 18 neocortical structures from the Institut National de la
Recherche Agronomique (INRA) atlas (28) (Supplemental Data
File 3). This revealed a range of positive treatment effects on cortical thickness in most cortical regions, with a shift in thickness
histograms closer to WT values in the rhPPT1-treated CLN1R151X
sheep (Figure 5C, with data from all regions in Supplemental Data
File 3). These effects were not uniform across all cortical regions
(Figure 5D), being more pronounced rostrally than in caudal cortical areas, with a few regions not benefitting from rhPPT1 treat-
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Figure 5. Therapeutic effect of i.c.v. administration of rhPPT1 in CLN1R151X sheep. (A) Gross anatomical examination and (B) structural MRI analysis
showed a positive treatment effect of i.c.v. administration of rhPPT1 (CLN1R151X + rhPPT1) compared with untreated CLN1R151X sheep and WT controls showing an overall reduction in cerebral and cerebellar atrophy in rhPPT1-treated CLN1R151X sheep. (C) Histograms of individual measures of cortical thickness in
the pre- and post-cruciate gyri showing the extent of treatment effect in these regions, with the movement of values in rhPPT1-treated CLN1R151X sheep
(green) moving closer to those for WT sheep (blue) than for untreated CLN1R151X controls (see Supplemental Table 1 and Supplemental Data File 1 for all
cortical thicknesses). (D) Solid 3D representation showing colored INRA ovine atlas (24) cortical regions in which a significant treatment effect upon individual thickness measurements was detected. ANOVA (ERT > untreated, P < 0.0001). Yellow and green colors indicate the magnitude of this effect, with
no significant treatment effect detected in the gray cortical regions (subcortical structures not analyzed). Yellow indicates regions where the mean cortical
thickness values for rhPPT1-treated CLN1R151X sheep were closer to WT values (greater treatment effect), and green represents regions in which these values were closer to those of untreated CLN1R151X sheep (positive treatment effect).

ment (data from all regions summarized in Supplemental Data
File 1 and Supplemental Table 1).
We also performed a neuropathological analysis of WT sheep,
untreated CLN1R151X sheep, and rhPPT1-treated CLN1R151X sheep
brains. We analyzed previously identified affected brain regions
(20) including the primary somatosensory cortex, at both the level
of the i.c.v. catheter (located in the rostral somatosensory cortex)
and of the thalamus (the caudal somatosensory cortex), in addition to the thalamus itself. We observed an overall reduction in
astrocytosis, microglial activation, and autofluorescent storage
material (AFSM) accumulation (Figure 6A) in the rhPPT1-treated
CLN1R151X sheep compared with the untreated CLN1R151X sheep. The
thickness of the primary somatosensory cortex was moderately
increased in the rhPPT1-treated CLN1R151X sheep as compared with
the untreated CLN1R151X sheep (Figure 6B). This finding correlated
with our gross anatomical and imaging observations (Figure 5).

Discussion

Devising an effective treatment strategy for CLN1 disease is a
particularly difficult challenge. In addition to its early onset and
rapid progression, this disorder affects widespread and anatomically distant regions of the CNS, all of which need treatment.
CLN1 disease is theoretically amenable to gene therapy via CNS
delivery of the CLN1 gene or, in ERT, via CNS delivery of recombinant PPT1 enzyme (3, 7). Although gene therapy for CLN1 disease
has shown promise in preclinical studies, its effects are relatively
localized, and, compared with its use in CLN2 disease, it is less
effective (23). At present, there remain limitations for the immediate clinical translation of gene therapy including transduction efficiency, immune response to viral vectors, and appropriate routes
of administration to maximize biodistribution (29–31), and work
is ongoing to overcome these obstacles. We therefore reasoned
that ERT, with its potential to treat the PPT1-deficient CNS, could
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Figure 6. Therapeutic effect on neuropathology of i.c.v. administration of rhPPT1 to CLN1R151X sheep. (A) Representative immunofluorescence images of
the cortex and thresholding imaging analysis (n = 2) of WT, i.c.v. rhPPT1–treated (CLN1R151X + rhPPT1), and untreated CLN1R151X sheep showing a reduction in
markers for astrocytosis (GFAP), microglial activation (Iba1), and AFSM accumulation across the rostral and caudal regions of the somatosensory cortex
as well as the thalamus. A reduction was seen across all the markers in rhPPT1-treated CLN1R151X sheep compared with untreated CLN1R151X sheep, although
these did not reach WT levels. Scale bar: 50 μm. (B) Measurements of cortical thickness in the rostral and caudal somatosensory cortices (and averaged
values) showing slightly increased values in rhPPT1-treated CLN1R151X sheep compared with untreated CLN1R151X sheep. Data represent the mean ± SEM.

represent a means to rapid and potentially more effective translation, despite potential challenges such as the need for repeated
enzyme delivery, the attendant risk of port-associated infections,
and potential immune responses to the exogenous protein (3, 32,
33). Our data show that repeated dosing of rhPPT1 can serve as
an effective enzyme replacement strategy for CLN1 disease, with
demonstrable efficacy across both small and large animal models
of this fatal disorder.
Having prepared rhPPT1 with favorable uptake properties,
the key to the success of our ERT strategy for CLN1 disease was
defining the method for delivering this enzyme. The enzyme
needs to be administered in sufficient amounts to improve disease
outcomes in both the brain and spinal cord (15, 23). Such enzyme
administration to the CSF could plausibly be achieved by either
i.c.v. or i.t. delivery. We reasoned that dosing rhPPT1 i.t. would be
a suitable means of treating the significant spinal pathology that
occurs in Cln1−/− mice (15, 16, 23). While i.c.v. infusions would treat
affected brain regions, they potentially may not effectively reach
the spinal cord, although our data suggest that i.c.v. delivery did
in fact reach the lumbar spinal cord of the sheep relatively quickly
8

(Supplemental Figure 6B). Nevertheless, on the basis of our previous gene therapy study in mice (23), we opted to test the potential
of either route of administration, comparing i.c.v. and i.t. rhPPT1
delivery in mice, in addition to combined administration via both
routes. Our data show that, regardless of the route of delivery,
repeated administration of rhPPT1 to the CSF was well tolerated
in Cln1−/− mice. However, compared with i.c.v. delivery, there was
less overall therapeutic benefit in the brain after i.t. rhPPT1 delivery. Splitting the same total dose of rhPPT1 across both delivery
routes was also less effective by all outcome measures, suggesting that a certain threshold of rhPPT1 activity must be reached
for ERT to be effective. Taken together, our Cln1−/− mouse data
revealed that i.c.v. administration alone provided rhPPT1 biodistribution that was sufficient to reach both the brain and spinal
cord. This is consistent with the greater efficacy of i.c.v. rhPPT1
infusions in Cln1−/− mice according to both motor performance
and pathological outcome measures.
Although mouse models provide a valuable testing ground for
preclinical strategies, many promising approaches fail to be translated into successful clinical treatments. This is not surprising,
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given the considerable differences in the relative complexity and
physical size of the CNS between mice and humans, in addition
to considerable species differences in drug metabolism (6). Large
animal models represent a crucial intermediate test system that is
well suited to determine how to adapt drug delivery and dosing to
successfully treat a larger and more complex CNS. This approach
was successful in the preclinical testing of i.c.v. enzyme replacement therapy for CLN2 disease, the late-infantile form of NCL
(22, 34, 35). This led to the first FDA-approved disease-limiting
therapy for any neuronopathic LSD (6). Such preclinical studies
in either dogs or sheep have mostly relied on naturally occurring
mutants. However, the advent of modern gene editing methods
such as CRISPR/Cas9 allowed us to generate a CLN1R151X sheep
model with a common human disease–causing mutation (20).
This model was specifically created for the purpose of testing how
to scale up preclinical strategies that show efficacy in Cln1−/− mice
for human translation. This sheep model also allowed us to test
outcome measures that might feasibly be used in a subsequent
human clinical trial. We are still developing suitable neurological
outcome assessment measurements for use in CLN1R151X sheep
(20), including maze testing of cognitive function and other neurological tests similar to those performed in naturally occurring
NCL sheep models (36, 37). However, our data revealed that quantitative MRI could detect treatment effects in sheep using a widely available human clinical MRI system with a standard clinical
sequence and a widely used and validated human post-processing
approach. This is encouraging for the subsequent use of such an
imaging methodology in children with CLN1 disease (38).
The demonstrable efficacy of rhPPT1 across both mouse
and sheep models of CLN1 disease indicates the value of such
a cross-species approach for developing a successful treatment
strategy. While this study was focused on a single rare disorder,
this approach has broader applicability for developing therapies
for a range of similar conditions. ERT with rhPPT1 successfully attenuated disease progression in Cln1−/− mice and CLN1R151X
sheep. As early diagnosis of CLN1 disease becomes more feasible, having an effective means to intervene therapeutically would
completely alter clinical practice. In order to arrive at complete
“normalization” of disease, it may be necessary to achieve a sustained and higher concentration of PPT1 in the CNS. Increasing
the frequency of enzyme infusions or administering a higher dose
of enzymes could accomplish this, at least acutely, in Cln1−/− mice
(Supplemental Figure 1C), and it will be important to test such
strategies in chronic treatment studies. Alternatively, the cellular
uptake of PPT1 could be further improved by engineering a highly
phosphorylated version, as has been shown in vitro for other lysosomal enzymes (39). It is also possible that initiating treatment
earlier, using recombinant sheep PPT1 or an alternate cell line to
produce enzymes may further improve efficacy in CLN1R151X sheep.
In addition, it will also be important to treat other affected organs
such as the eye and other sites outside the CNS, which are unlikely
to be treated effectively by i.c.v. delivery of rhPPT1.
Overall, we have shown that repeated dosing of ERT to treat
CLN1 disease can be a viable therapeutic strategy and that the
cross-species pipeline with defined outcome measures will facilitate dosing and biodistribution studies. Together, these represent
what we believe to be a significant step forward in the develop-

ment of a clinical therapy for this fatal disease that currently lacks
an FDA-approved treatment.

Methods

Study design. The goal of this study was to test the efficacy of repeated
delivery of 20 μg rhPPT1 enzyme to the CNS of PPT1-deficient mice
(Cln1−/−) and sheep (CLN1R151X). First, Cln1−/− mice were given monthly
infusions of rhPPT1 enzyme starting at P1 via the i.c.v., i.t., or combined i.c.v. plus i.t. (split dose) routes for 6 months, with appropriate
controls — vehicle-treated Cln1−/− mice and naive WT mice. Intracerebrovascular infusions from P30 were done via a chronic cannula
placed in the left ventricle. Mice were assessed at monthly intervals for
changes in motor performance using semiautomated gait analysis and
rotarod paradigms. At 6 months (end-stage disease), the mice were
sacrificed and the collected tissue analyzed for enzymatic activity and
neuropathology. All analyses were performed in a blinded manner
with regard to genotype and treatment. Having established the most
effective route of rhPPT1 administration in mice, CLN1R151X sheep,
starting at 6 months of age, were given monthly infusions of rhPPT1
or vehicle for 7 months via a surgically implanted i.c.v. cannula. At 13
months, the sheep were sacrificed and subjected to MRI within 1 hour
of sacrifice, and tissue was subsequently collected for biochemical and
histopathological analysis. An acute dose-response study was also performed in 2-month-old Cln1−/− mice to determine whether delivering
a higher, 40 μg, dose of rhPPT1 would further increase CNS levels of
PPT1 activity above those seen with a 20 μg dose.
Animals. Congenic Cln1−/− and WT mice were previously engineered at the University of Texas Southwestern Medical Center in
Dallas, Texas (19), and were maintained on a C57Bl/6J background.
CLN1R151X sheep were previously engineered at the Roslin Institute,
University of Edinburgh, Easter Bush, Scotland, United Kingdom (20),
and were now generated by breeding heterozygous sheep. Homozygous CLN1R151X sheep were confirmed by appropriate genotyping (20).
See Supplemental Methods for further details.
rhPPT1 enzyme formulation and administration. The rhPPT1 used
in this study is identical to that previously produced and purified
using Chinese hamster ovary (CHO) cells as described previously (17)
and characterized by Western blotting. Purified PPT1 was tested by a
CI-MPR assay for binding affinity to the immobilized CI-MPR, and
the half-maximal binding (KD) was determined as described before
(17). Glycopeptide composition (glycosylation and phosphorylation) was determined by liquid chromatography high-resolution UV
mass spectrometry (LC-UV-HRMS), as described previously (17). All
mice, regardless of route of administration (i.c.v., i.t., or i.c.v. + i.t.),
received the same total dose of enzyme — 5 μL rhPPT1 at 4 mg/mL
— as monthly infusions for 6 months. Six-month-old CLN1R151X sheep
received 1 mL of the same 4 mg/mL rhPPT1 preparation, infused at
a rate of 0.6 mL/h. These infusions were given monthly starting at 6
months and ending at 13 months of age. See Supplemental Methods
for further details.
Murine behavioral analysis. Rotarod testing using stationary (60 s)
and constant speed (2.5 rpm) paradigms (23) and gait analysis using
the CatWalk XT system (Noldus Information Technology) were performed as previously described (15) using 10 mice per group at monthly intervals, beginning at 1 month until 6 months. All behavioral tests
were performed after appropriate habituation and training. See Supplemental Methods for further details.
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Ovine MRI analysis. Sheep were imaged within 1 hour of being
sacrificed. Structural sequences included T1- and T2-weighted 3D
imaging and fluid-attenuated inversion recovery (FLAIR) imaging
with whole brain coverage. Apparent diffusion coefficients were
calculated using readout segmentation of long variable echo-trains
(RESOLVE) to minimize echoplanar distortions. The extracted brains
were classified using the advanced normalization tools (ANTs) for 3
tissue classes (CSF, GM, and white matter [WM]). Extracted brains
were then coregistered with the INRA brain-only template (28). Total
brain volume was calculated from a combination of the GM and WM
tissue class probability maps. All metrics were adjusted for total intracranial volume (GM + WM + CSF), total brain volume (GM + WM), and
total GM volume. We have previously described that areas of cortical
GM undergo differential degrees of atrophy in homozygous CLN1R151X
sheep (20), and therefore regional GM volumes were normalized to
total GM volume to assess for the relative preservation of cortical
regions. See Supplemental Methods for further details.
Tissue collection and histopathological analysis. Mouse brain and
spinal cord tissues were collected for biochemical and histological
processing as previously described (23). Sheep tissues were collected for biochemical analyses and histological processing as previously
described (20). Mouse brains and spinal cords were stained for cresyl
fast violet as well as immunostained for glial markers and storage material as previously described (15). Sheep brain sections were stained
using a free-floating immunofluorescence protocol for astrocytes (glial
fibrillary acidic protein [GFAP]) and microglia (ionized calcium-binding adapter molecule 1 [Iba1])], or left unstained to directly visualize
AFSM (see Supplemental Methods for further details). Cresyl fast violet–stained tissue was analyzed for cortical thickness and neuron counts
as described before (14, 15), and immunostained tissue and tissue for
AFSM were analyzed using thresholding image analysis as described
previously (15) (see Supplemental Methods for further details).
Analysis of enzyme activity. Mouse and sheep tissues were homogenized and analyzed for PPT1 activity using the 4-MU-palmitate fluorometric assay and normalized to total protein. Secondary elevations
of another lysosomal enzyme, β-glucuronidase, were determined
using the 4-MU-β-d-glucuronide fluorometric assay and normalized
to total protein as previously described (23, 40).
Statistics. All measurements for histological processing were performed with the researcher blinded to genotype. All statistical analyses
were performed using GraphPad Prism (GraphPad Software). Gait and
rotarod data were analyzed using a 2-way ANOVA with post hoc Bonferroni’s correction, and all biochemical and histological analyses were
done using a 1-way ANOVA with post hoc Bonferroni’s correction. In all
instances, a P value of 0.05 or less was considered significant.
Study approval. All procedures were performed in accordance
with NIH guidelines under a protocol approved by the IACUC of
Washington University School of Medicine (protocols 2018-0215 and
21-0292). Sheep studies were reviewed and approved by the Animal
Welfare and Ethical Review Board (AWERB) of the Roslin Institute
1. Uzor NE, et al. Peroxisomal dysfunction in neurological diseases and brain aging. Front Cell
Neurosci. 2020;14:44.
2. Wang Y, et al. Mitochondrial dysfunction in neurodegenerative diseases and the potential countermeasure. CNS Neurosci Ther. 2019;25(7):816–824.
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and conducted under the authority of the UK Home Office (equivalent
of an IACUC). The work detailed here was carried out under license
number PEFC7DB6A.
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